CNS Amyloid-β, Soluble APP-α and-β Kinetics during BACE Inhibition

Journal of Neuroscience

Volumn 34, Issue 24, 2014, Pages 8336-8346

  Dobrowolska, Justyna A ^a,c   Michener, Maria S ^b   Wu, Guoxin ^b   Patterson, Bruce W ^a   Chott, Robert ^a   Ovod, Vitaliy ^a   Pyatkivskyy, Yuriy ^a,e   Wildsmith, Kristin R ^a,d   Kasten, Tom ^a   Mathers, Parker ^b   Dancho, Mandy ^b   Lennox, Christina ^b   Smith, Brad E ^b   Gilberto, David ^b   McLoughlin, Debra ^b   Holder, Daniel J ^b   Stamford, Andrew W ^b   Yarasheski, Kevin E ^a   Kennedy, Matthew E ^b   Savage, Mary J ^b   Bateman, Randall J ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d GENENTECH INC   (United States)

^e WATERS CORPORATION   (United States)

Author keywords

Amyloid beta; Amyloid precursor protein; BACE inhibitor; SAPP sAPP ; SILK

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN ALPHA; AMYLOID PRECURSOR PROTEIN BETA; BETA SECRETASE; BETA SECRETASE INHIBITOR; CARBON 13; LEUCINE; MBI 5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CENTRAL NERVOUS SYSTEM; CISTERNA MAGNA; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MALE; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; WESTERN BLOTTING;

AMYLOID BETA; AMYLOID PRECURSOR PROTEIN; BACE INHIBITOR; SAPPΑ; SAPPΒ; SILK;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CARBON ISOTOPES; CELL LINE, TUMOR; CENTRAL NERVOUS SYSTEM; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; IMMUNOPRECIPITATION; LEUCINE; MACACA MULATTA; MASS SPECTROMETRY; NEUROBLASTOMA; PEPTIDE FRAGMENTS; TRANSFECTION;

EID: 84902213062     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0540-14.2014     Document Type: Article

References (50)

1. Alexopoulos P, Tsolakidou A, Roselli F, Arnold A, Grimmer T, Westerteicher C, Leante MR, Förstl H, Livrea P, Kurz A, Perneczky R (2012) Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid. Alzheimers Dement 8:304-311. CrossRef Medline
2. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM (2006) Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12:856-861. CrossRef Medline
3. Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE (2007) Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrom 18:997-1006. CrossRef Medline
4. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM (2009) A gamma-secretase inhibitor decreases amyloid-β production in the central nervous system. Ann Neurol 66:48-54. CrossRef Medline
5. Bernier F, Sato Y, Matijevic M, Desmond H, McGrath S, Burns L, Kaplow JM, Albala B (2013) Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF. Alzheimers Dement 9:886.
6. Brinkmalm G, Brinkmalm A, Bourgeois P, Persson R, Hansson O, Portelius E, Mercken M, Andreasson U, Parent S, Lipari F, Ohrfelt A, Bjerke M, Minthon L, Zetterberg H, Blennow K, Nutu M (2013) Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease. Brain Res 1513:117-126. CrossRef Medline
7. Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA (1993) Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A 90:2092-2096. CrossRef Medline
8. Cook JJ, Wildsmith KR, Gilberto DB, Holahan MA, Kinney GG, Mathers PD, Michener MS, Price EA, Shearman MS, Simon AJ, Wang JX, Wu G, Yarasheski KE, Bateman RJ (2010) Acute gamma-secretase inhibition of nonhuman primate CNS shifts Amyloid Precursor Protein (APP) metabolism from amyloid-β production to alternative APP fragments without Amyloid-β rebound. J Neurosci 30:6743-6750. CrossRef Medline
9. Cumming JN, Smith EM, Wang L, Misiaszek J, Durkin J, Pan J, Iserloh U, Wu Y, Zhu Z, Strickland C, Voigt J, Chen X, Kennedy ME, Kuvelkar R, Hyde LA, Cox K, Favreau L, Czarniecki MF, Greenlee WJ, McKittrick BA, et al. (2012) Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. Bioorg Med Chem Lett 22:2444-2449. CrossRef Medline
10. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G (2005) Mechanismbased pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm Res 22:1432-1437. CrossRef Medline
11. Dobrowolska J, Mawuenyega KG, Bateman RJ (2008) The metabolism of amyloid precursor protein as measured in human cerebrospinal fluid. Soc Neurosci Abstr 34:138-2.
12. Dobrowolska JA, Kasten T, Huang Y, Benzinger TL, Sigurdson W, Ovod V, Morris JC, Bateman RJ (2014) Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLo S One 9:e89998. CrossRef Medline
13. Egan MF, Forman MS, Palcza J, Tseng J, Leempoels J, Ramael S, Han D, Jhee S, Ereshefsky L, Tanen M, Laterza O, Dockendorf M, Krishna G, Ma L, Wagner JA, Troyer MD (2012) The novel BACE inhibitor MK-8931 dramatically lowers CSF Aβ peptides in healthy subjects following single and multiple dose administration. 5th conference clinical trials on Alzheimer's disease: October 29-31, 2012, Grimaldi Forum, Convention Center, Monte Carlo. J Nutr Health Aging 16:797. CrossRef
14. Forman MS, Palcza J, Tseng J, Dockendorf M, Canales C, Apter J, Backonja M, Bryan E, Ereshefsky L, Gevorkyan H, Jhee S, Ostler R, Zari A, Kleijn HJ, Laterza O, Ma L, Stone J, Tanen M, Wagner JA, Troyer MD (2013) The novel BACE inhibitor MK-8931 dramatically lowers CSF Aβ peptide in patients with mild to moderate Alzheimer's disease. AD/PDTM 2013, the 11th International Conference on Alzheimer's and Parkinson's Diseases, Florence, Italy.
15. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC (2002) β-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59:1381-1389. CrossRef Medline
16. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R, Kawamoto M, Hirai K, Terauchi J, Sakura Y, Kakihana M, Kato K, Iwatsubo T, Miyamoto M (2010) A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci 30:11157-11166. CrossRef Medline
17. Gabelle A, Roche S, Gény C, Bennys K, Labauge P, Tholance Y, Quadrio I, Tiers L, Gor B, Chaulet C, Vighetto A, Croisile B, Krolak-Salmon P, Touchon J, Perret-Liaudet A, Lehmann S (2010) Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid. Brain Res 1357:175-183. CrossRef Medline
18. Gilberto DB, Zeoli AH, Szczerba PJ, Gehret JR, Holahan MA, Sitko GR, Johnson CA, Cook JJ, Motzel SL (2003) An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys. Contemp Top Lab Anim Sci 42:53-59. Medline
19. Holsinger RM, Lee JS, Boyd A, Masters CL, Collins SJ (2006) CSF BACE1 activity is increased in CJD and Alzheimer disease versus other dementias. Neurology 67:710-712. CrossRef Medline
20. Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, Naylor A, Jeffrey P, Gonzalez MI, Dingwall C, Michel A, Redshaw S, Davis JB (2007) Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem 100:802-809. CrossRef Medline
21. Irizarry MC, Locascio JJ, Hyman BT (2001) β-site APP cleaving enzyme m RNAexpression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging. Am J Pathol 158:173-177. CrossRef Medline
22. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jönsson EG, et al. (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488:96-99. CrossRef Medline
23. Kim ML, Zhang B, Mills IP, Milla ME, Brunden KR, Lee VM (2008) Effects of TNFα-converting enzyme inhibition on amyloid β production and APP processing in vitro and in vivo. J Neurosci 28:12052-12061. CrossRef Medline
24. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Bürger K, Hampel H, Frölich L, Wolf S, Prinz B, Jahn H, Luckhaus CH, Perneczky R, Hüll M, Schröder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, et al. (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 15:138-145. CrossRef Medline
25. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y (2004) Amyloid β peptide load is correlated with increasedβ-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A 101:3632-3637. CrossRef Medline
26. Malamas MS, Robichaud A, Erdei J, Quagliato D, Solvibile W, Zhou P, Morris K, Turner J, Wagner E, Fan K, Olland A, Jacobsen S, Reinhart P, Riddell D, Pangalos M (2010) Design and synthesis of aminohydantoins as potent and selective humanβ-secretase (BACE1) inhibitors with enhanced brain permeability. Bioorg Med Chem Lett 20:6597-6605. CrossRef Medline
27. Mandal M, Zhu Z, Cumming JN, Liu X, Strickland C, Mazzola RD, Caldwell JP, Leach P, Grzelak M, Hyde L, Zhang Q, Terracina G, Zhang L, Chen X, Kuvelkar R, Kennedy ME, Favreau L, Cox K, Orth P, Buevich A, et al. (2012) Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation. J Med Chem 55:9331-9345. CrossRef Medline
28. Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, Brinkmalm G, Lundkvist J, Jacobson LH, Perrot L, Neumann U, Borghys H, Mercken M, Dhuyvetter D, Jeppsson F, Blennow K, Portelius E (2012) BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system. PLo S One 7:e31084. CrossRef Medline
29. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, et al. (2011) Robust central reduction of Amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci 31:16507-16516. CrossRef Medline
30. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS betaamyloid in Alzheimer's disease. Science 330:1774. CrossRef Medline
31. Oltersdorf T, Ward PJ, Henriksson T, Beattie EC, Neve R, Lieberburg I, Fritz LC (1990) The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway. J Biol Chem 265:4492-4497. Medline
32. Ortega F, Stott J, Visser SA, Bendtsen C (2013) Interplay betweenα-, β-, and γ-secretases determines biphasic amyloid-β protein level in the presence of a γ-secretase inhibitor. J Biol Chem 288:785-792. CrossRef Medline
33. Perez RG, Squazzo SL, Koo EH (1996) Enhanced release of amyloid β-protein from codon 670/671 "Swedish" mutant β-amyloid precursor protein occurs in both secretory and endocytic pathways. J Biol Chem 271:9100-9107. CrossRef Medline
34. Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K (2011) A novel pathway for amyloid precursor protein processing. Neurobiol Aging 32:1090-1098. CrossRef Medline
35. Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TL, Bateman RJ (2013) Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med 5:189ra77. CrossRef Medline
36. Rosén C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H (2012) Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease. Neuromolecular Med 14: 65-73. CrossRef Medline
37. Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, Gregro AR, Hazuda D, Hochman JH, Holloway K, Jin L, Kahana J, Lai MT, Lineberger J, McGaughey G, Moore KP, Nantermet P, et al. (2009) First demonstration of cerebrospinal fluid and plasma Aβ lowering with oral administration of a β-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther 328:131-140. CrossRef Medline
38. Savage M, Holder D, Wu G, Kaplow JM, Siuciak J, Potter W, Alzheimer's Disease Neuroimaging Initiative (ADNI), Foundation for NIH Biomarkers Consortium CSF Proteomics Project Team (2013) Soluble BACE activity and s APPβ levels do not differentiate Alzheimer's disease and age-matched control cerebrospinal fluid in the ADNI-1 cohort. Alzheimers Dement 9:P201. CrossRef
39. Stamford AW, Scott JD, Li SW, Babu S, Tadesse D, Hunter R, Wu Y, Misiaszek J, Cumming JN, Gilbert EJ, Huang C, McKittrick BA, Hong L, Guo T, Zhu Z, Strickland C, Orth P, Voigt JH, Kennedy ME, Chen X, et al. (2012) Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS Aβ reduction. ACS Med Chem Lett 3:897-902. CrossRef Medline
40. Takahashi H, Fukumoto H, Maeda R, Terauchi J, Kato K, Miyamoto M (2010) Ameliorative effects of a non-competitive BACE1 inhibitor TAK-070 on Aβ peptide levels and impaired learning behavior in aged rats. Brain Res 1361:146-156. CrossRef Medline
41. Truong AP, Tóth G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, et al. (2010) Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett 20:6231-6236. CrossRef Medline
42. Van Maanen E, van Steeg T, Ahsman M, Savage MJ, Michener MS, Kleijn HJ, Danhof M, Stone J (2013) A systems pharmacology model of the APP processing pathway in Alzheimer's Disease. American Conference on Pharmacometrics, Ft. Lauderdale, FL.
43. Verheijen JH, Huisman LG, van Lent N, Neumann U, Paganetti P, Hack CE, Bouwman F, Lindeman J, Bollen EL, Hanemaaijer R (2006) Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem 52:1168-1174. CrossRef Medline
44. Weidemann A, König G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K (1989) Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 57:115-126. CrossRef Medline
45. Wolfe RR, Chinkes DL (2005) Isotope tracers in metabolic research: principles and practice of kinetic analysis, Ed 2. Hoboken, NJ: Wiley.
46. Wu G, Sankaranarayanan S, Hsieh SH, Simon AJ, Savage MJ (2011) Decrease in brain soluble amyloid precursor protein β (s APPβ) in Alzheimer's disease cortex. J Neurosci Res 89:822-832. CrossRef Medline
47. Wu G, Sankaranarayanan S, Wong J, Tugusheva K, Michener MS, Shi X, Cook JJ, Simon AJ, Savage MJ (2012) Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease. J Neurosci Res 90:2247-2258. CrossRef Medline
48. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y (2003) Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9:3-4. CrossRef Medline
49. Yarasheski KE, Smith K, Rennie MJ, Bier DM (1992) Measurement of muscle protein fractional synthetic rate by capillary gas chromatography/ combustion isotope ratio mass spectrometry. Biol Mass Spectrom 21: 486-490. CrossRef Medline
50. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ, Blennow K (2008) Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 65:1102-1107. CrossRef Medline